Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.
نویسندگان
چکیده
OBJECTIVE To differentiate juvenile polymyositis (PM) and muscular dystrophy, both of which may present with chronic muscle weakness and inflammation. METHODS We studied 39 patients with probable or definite juvenile PM and 9 patients with muscular dystrophies who were initially misdiagnosed as having juvenile PM. Differences in demographic, clinical, and laboratory results; outcomes; and treatment responses were evaluated by Fisher's exact and rank sum tests. Random forests classification analysis and logistic regression were performed to examine significant differences in multivariable models. RESULTS Clinical features and serum muscle enzyme levels were similar between juvenile PM and dystrophy patients, except 89% of dystrophy patients had muscle atrophy compared with 46% of juvenile PM patients. Dystrophy patients had a longer delay to diagnosis (median 12 versus 4 months) and were less frequently hospitalized than juvenile PM patients (22% versus 74%). No dystrophy patients, but 54% of juvenile PM patients, had a myositis autoantibody. Dystrophy patients more frequently had myopathic features on muscle biopsy, including diffuse variation of myofiber size, fiber hypertrophy, and myofiber fibrosis (44-100% versus 8-53%). Juvenile PM patients more frequently had complex repetitive discharges on electromyography and a complete response to treatment with prednisone or other immunosuppressive agents than dystrophy patients (44% versus 0%). Random forests analysis revealed that the most important features in distinguishing juvenile PM from dystrophies were myositis autoantibodies, clinical muscle atrophy, and myofiber size variation on biopsy. Logistic regression confirmed muscle atrophy, myofiber fibrosis, and hospitalization as significant predictors. CONCLUSION Muscular dystrophy can present similarly to juvenile PM. Selected clinical and laboratory features are helpful in combination in distinguishing these conditions.
منابع مشابه
Handbook of Treatment of Acute Poisoning
D. Adams, M.D. (Pp. x + 270; figs. 47. 32s. 6d.) Edinburgh and London: E. & S. Livingstone, 1958. IT has only been in comparatively recent years that the position of muscular dystrophy as a clinical entity has been seriously challenged by the discovery that a somewhat similar clinical picture may be seen in polymyositis, dermatomyositis, and scleroderma. The authors, who have based their monogr...
متن کاملChronic focal polymyositis in the adult.
Four patients with chronic focal polymyositis are described. Treatment with steroids appeared to halt clinical progression. The clinical features in all four cases were so strikingly similar as to constitute a syndrome which can be mistaken for muscular dystrophy or spinal muscular atrophy unless investigated fully.
متن کاملExpression of B7-homolog 1 in Polymyositis.
OBJECTIVES Costimulatory molecules are increasingly recognized as crucial for stimulation and/ or inhibition of immune responses. The present study was undertaken to examine the expression and functional relevance of B7-homolog 1 (B7-H1) attributed significant immunoregulatory functions in polymyositis in vivo. METHODS 43 muscle biopsy specimens obtained from patients with polymyositis, 26 ca...
متن کاملCD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.
OBJECTIVE Dysferlin is a sarcolemmal protein that plays an important role in membrane repair by regulating vesicle fusion with the sarcolemma. Mutations in the dysferlin gene (DYSF) lead to multiple clinical phenotypes, including Miyoshi myopathy (MM), limb girdle muscular dystrophy type 2B (LGMD 2B), and distal myopathy with anterior tibial onset (DMAT). Patients with dysferlinopathy also show...
متن کاملThe Diagnostic Value of Utrophin in Mild Dystrophinopathy (Becker Muscular Dystrophy)
Background and Objective: Becker Muscular Dystrophy (BMD) is a subtype of dystrophinopathies and designated as “mild form of dystrophinopathy”. The frequency rate of the disease is 1:18000 to 1:30000 in different populations and the symptoms are presented at about 8-9 years of age. The diagnostic panel composed of Serum Ceratin Kinase (SCK) measurement, Electromyography (EMG), and as a major...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Arthritis care & research
دوره 65 12 شماره
صفحات -
تاریخ انتشار 2013